Key PointsAbbVie continues to grow its revenue base by successfully transitioning from Humira to its next-generation immunology drugs.
Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.